We sent this letter to Senate Majority Leader Schumer and Minority Leader McConnell:
"Establishing a $35 monthly copay cap on insulin for individuals with both commercial insurance and Medicare will greatly benefit millions of Americans who rely on insulin to survive. In particular, this out-of-pocket (OOP) limit in the commercial insurance market will help nearly 40 percent of people with diabetes who have private insurance, including large numbers of working Americans who are struggling to make ends meet in this economy.
The price of insulin nearly tripled between 2002 and 2013, and the trend upward has continued over the past decade, leading to substantial increases in out-of-pocket costs for patients. Lack of access to affordable insulin will only become more dangerous for the diabetes community the longer Congress waits to act. We believe limiting out-of-pocket costs for insulin for those with commercial insurance and Medicare is a necessary step toward broader reforms to bring down the price of insulin for all Americans with diabetes who need this life-saving medication."
Read the Full Letter